参考文献/References:
[1] 李祥, 郑红梅, 吴奇, 等. 阿帕替尼在恶性肿瘤中的研究进展[J]. 临床外科杂志, 2017, 25（4）：314-315. LI Xiang, ZHENG Hongmei, WU Qi, et al. Research progress of apatinib on malignant tumor[J]. Journal of Clinical Surgery, 2017, 25(4): 314-315.
[2] LI Jin, QIN Shukui, XU Jianming, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial[J]. Journal of Clinical Oncology, 2013, 31(26): 3219-3225.
[3] LESCHE D, SIGURDARDOTTIR V, SETOUD R, et al. CYPP3A5*3 and PPOR*28 genetic variants influence the required dose of tacroloimus in heart transplant recipients[J]. Therapeutic Drug Monitoring, 2014, 36(6): 710-715.
[4] LIU Jiayong, ZHU Baorang, WANG Yudong, et al. The efficacy and safety of apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis[J]. International Journal of Clinical Oncology, 2020, 25(6): 1195-1205.
[5] SONG Zizheng, ZHAO Lifen, ZUO Jing, et al. Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous nonsmall cell lung cancer in patients who progressed after standard therapy and analysis of the KDR gene polymorphism[J]. Onco Targets and Therapy, 2020, 13: 603-613.
[6] GENG Nan, DING Cuimin, LIU Zhikun, et al. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a realworld retrospective study[J]. International Journal of Clinical Oncology, 2021, 26(4): 670-683.
[7] YAN Zhen, GU Yuanyuan, HU Xiaodi, et al. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism[J].Oncology Letters, 2020, 20(3): 3035-3045.
[8] 赵瑞华, 周亚楠, 李鹤, 等. 阿帕替尼对晚期非小细胞肺癌患者的疗效及VEGFR2-906T>C 多态性位点的影响[J]. 中华医学杂志, 2019, 99(2): 105-110. ZHAO Ruihua, ZHOU Ya’nan, LI He, et al. Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients[J]. National Medical Journal of China, 2019, 99(2): 105-110.
[9] 石瑶瑶. 阿帕替尼治疗恶性肿瘤不良反应的单中心观察性研究[D]. 济南：山东大学, 2017：1-44. SHI Yaoyao. Single-center observational study of adverse drug reaction of apatinib utilized in malignant tumor therapy[D]. Jinan: Shandong University, 2017: 1-44.
[10] 曹烨, 万邦喜, 苏敏实. 药物临床试验安全评价·广东共识(2020 年版)[J]. 今日药学, 2020, 30(11): 731-740. CAO Ye, WANG Bangxi, SU Minshi. Consensus of expert on safety evaluation of drug clinical trial in Guangdong (Version 2020)[J]. Pharmacy Today, 2020, 30(11): 731-740.
[11] U. S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 0[EB/OL]. (2017-11-27)(2023-07-18). https://ctep. cancer. gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7. pdf.
[12] GU Xiaoying, ZHANG Su, YANG Xuejiao, et al. Drugrelated adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma[J].BMC Gastroenterology, 2022, 22(1): 1-9.
[13] 郭九叶, 耿珊珊, 高月乔, 等. 北京地区新生儿细胞色素P450 单核苷酸多态性及其代谢表型分布的研究[J]. 现代检验医学杂志, 2018, 33(6): 9-12. GUO Jiuye, GENG Shanshan, GAO Yueqiao, et al. Distribution of single nucleotide polymorphisms of cytochrome P450 genes and metabolic phenotypes of newborn infants in Beijing area[J]. Journal of Modern Laboratory Medicine, 2018, 33(6): 9-12.
[14] NEYSHABURINEZHAD N, GHASIM H, ROUINI M, et al. Frequency of important CYP450 enzyme gene polymorphisms in the Iranian population in comparison with other major populations: a comprehensive review of the human data[J]. Journal of Personalized Medicine, 2021, 11(8): 804.
[15] 平军娇, 高永双, 邓顺顺, 等. 广东省中山地区汉族精神类疾病患者药物基因型及代谢表型分布研究[J]. 现代检验医学杂志, 2019, 34(3): 15-20, 24. PING Junjiao, GAO Yongshuang, DENG Shunshun, et al. Research on characteristics of drug genotypes and metabolic phenotypes in Chinese Han patients with severe mental illness in Zhongshan area of Guangdong province[J]. Journal of Modern Laboratory Medicine, 2019, 34(3): 15-20, 24.
[16] LI Jin, QIN Shukui, XU Jianming, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. Journal of Clinical Oncology, 2016, 34(13): 1448-1454.
[17] 范芳, 余炜, 刘捷, 等. 真实世界中阿帕替尼血药浓度研究[J]. 临床合理用药杂志, 2020, 13（5）：117-118. FAN Fang, YU Wei, LIU Jie, et al. The study on plasma concentration of apatinib in the real world[J].Chinese Journal of Clinical Rational Drug Use, 2020, 13(5): 117-118.
[18] L? Yajuan, ZHANG Yan, ZHANG Jiandong, et al. Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult:a case report and a review of the literature[J].Medicine(Baltimore), 2019, 98(46): e17787.
[19] 贾贝, 乔涌起, 范琳琳, 等. 一例贲门癌患者服用阿帕替尼发生缺血性脑卒中的病例分析[J]. 实用药物与临床,2020, 23(2): 176-180. JIA Bei, QIAO Yongqi, FAN Linlin, et al. Ischemic stroke due to taking apatinib in a patient with gastric cardia aderocarcinoma: a case report[J]. Practical Pharmacy and Clinical Remedies, 2020, 23(2): 176-180.
[20] REN Dengfeng, WANG Guoxin, ZHANG Yu, et al. Efficacy and safety of apatinib for elderly patients with advanced or metastatic gastric cancer after failure of at least first-line chemotherapy: a multi-center, singlearm, Phase II Study. [J]. Onco Targets and Therapy, 2021, 14: 4499-4508.
[21] ZHANG Yong, HAN Chun, LI Juan, et al. Efficacy and safety for apatinib treatment in advanced gastric cancer:a real world study[J]. Scientific Reports, 2017, 7(1): 13208.
相似文献/References:
[1]陈晓露.白细胞介素4基因多态性与结直肠癌的易感性[J].现代检验医学杂志,2015,30(05):105.[doi:10.3969/j.issn.1671-7414.2015.05.032]
CHEN Xiao-lu.Interleukin-4 Gene Polymorphisms and Colorectal Cancer Susceptibility[J].Journal of Modern Laboratory Medicine,2015,30(01):105.[doi:10.3969/j.issn.1671-7414.2015.05.032]
[2]朱琴芳,丁倩倩,俞钱,等.CD40-1C/T基因多态性与系统性红斑狼疮的相关性研究[J].现代检验医学杂志,2015,30(06):46.[doi:10.3969/j.issn.1671-7414.2015.06.013]
ZHU Qin-fang,DING Qian-qian,YU Qian,et al.Association of CD40 Gene Polymorphism
with the Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2015,30(01):46.[doi:10.3969/j.issn.1671-7414.2015.06.013]
[3]黄生金,郑利平,陆俊佳,等.广西地区壮族和汉族冠心病患者胱抑素C水平及其基因多态性的比较研究[J].现代检验医学杂志,2017,32(03):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
HUANG Sheng-jin,ZHENG Li-ping,LU Jun-jia,et al.Comparative Study of Cystatin C and Its Gene Polymorphism of Pati
ents
with Coronary Heart Disease between Zhuang and Han in Guangxi Region[J].Journal of Modern Laboratory Medicine,2017,32(01):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
[4]曹云,周晓,张晓艳,等.陕西省延安地区育龄女性MTHFR基因多态性和国内多地区相关报道比较分析2)[J].现代检验医学杂志,2019,34(01):62.[doi:10.3969/j.issn.1671-7414.2019.01.016]
CAO Yun,ZHOU Xiao,ZHANG Xiao-yan,et al.Comparative Analysis of MTHFR Gene Polymorphisms
in Women of Childbearing Age in Yan’an Area of Shaanxi Province
and Related Reports in Many Regions in China[J].Journal of Modern Laboratory Medicine,2019,34(01):62.[doi:10.3969/j.issn.1671-7414.2019.01.016]
[5]滕祥云,王新梦,刘 维,等.中国汉族结直肠癌患者 UGT1A1*28基因多态性分析[J].现代检验医学杂志,2019,34(06):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
TENG Xiang-yun,WANG Xin-meng,LIU Wei,et al.Polymorphism of UGT1A1*28 Gene in Han Patients with
Colorectal Cancer in China[J].Journal of Modern Laboratory Medicine,2019,34(01):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
[6]周 琰,王蓓丽,张春燕,等.消化道肿瘤患者MTHFR 基因多态性与5- 氟尿嘧啶化疗不良反应的相关性研究[J].现代检验医学杂志,2020,35(03):1.[doi:10.3969/j.issn.1671-7414.2020.03.001]
ZHOU Yan,WANG Bei-li,ZHANG Chun-yan,et al.Relationship between MTHFR Gene Polymorphisms and Adverse Events
by 5-FU in Gastrointestinal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(01):1.[doi:10.3969/j.issn.1671-7414.2020.03.001]
[7]洪雄新,李观强,杨 辉,等.2 型糖尿病患者ABCA1 R219K 基因多态性分布及其与血脂水平的相关性研究[J].现代检验医学杂志,2020,35(04):14.[doi:10.3969/j.issn.1671-7414.2020.04.004]
HONG Xiong-xin,LI Guan-qiang,YANG Hui,et al.Study on Distribution of ABCA1 R219K Gene Polymorphism and Its Correlation with Blood Lipid Levels for Type 2 Diabetes Mellitus Patients[J].Journal of Modern Laboratory Medicine,2020,35(01):14.[doi:10.3969/j.issn.1671-7414.2020.04.004]
[8]杨小柯,何柳媚,全湛柔,等.深圳地区人群乙型肝炎病毒携带者HLA-DRB1 等位基因多态性及关联性分析[J].现代检验医学杂志,2020,35(05):5.[doi:10.3969/j.issn.1671-7414.2020.05.002]
YANG Xiao-ke,HE Liu-mei,QUAN Zhan-rou,et al.Analysis of Allelic Polymorphism and Association of HLA-DRB1 in Hepatitis
B Virus Carriers in Shenzhen[J].Journal of Modern Laboratory Medicine,2020,35(01):5.[doi:10.3969/j.issn.1671-7414.2020.05.002]
[9]张姝,罗洁,许琦,等.贵州地区汉族阿尔茨海默症患者CYP2C19 基因多态性及代谢表型分析[J].现代检验医学杂志,2020,35(05):13.[doi:10.3969/j.issn.1671-7414.2020.05.004]
ZHANG Shu,LUO Jie,XU Qi,et al.Analysis of CYP2C19 Gene Polymorphism and Metabolic Phenotype in
Alzheimerdisease Patients of Han Nationality in Guizhou[J].Journal of Modern Laboratory Medicine,2020,35(01):13.[doi:10.3969/j.issn.1671-7414.2020.05.004]
[10]师文涛,白 蓉,黄剑林,等.陕西省延安地区汉族与国内其他地区育龄妇女 MTHFR 基因 C677T 位点基因型和等位基因分布研究[J].现代检验医学杂志,2020,35(06):78.[doi:doi:10.3969/j.issn.1671-7414.2020.06.019]
SHI Wen-tao,BAI Rong,HUANG Jian-lin,et al.Comparative Study on MTHFR Gene C677T Locus Genotype and AlleleDistribution between Han Nationality and Women of ChildbearingAge in Yan’an Area of Shaanxi Province[J].Journal of Modern Laboratory Medicine,2020,35(01):78.[doi:doi:10.3969/j.issn.1671-7414.2020.06.019]